BioNTech Pays $205 Million to Jump the FDA Queue

BioNTech SE (Nasdaq: BNTX) agreed on November 10 to acquire a US Food and Drug Administration Priority Review Voucher from Scholar Rock (Nasdaq: SRRK) for total cash consideration of $205 million, according to a company statement. The transaction remains subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act.

A voucher grants priority review for a single drug application, and BioNTech said it intends to use this one to support a future filing of an asset in its late-stage oncology pipeline, which it did not name. What changed hands is speed: a priority review cuts the FDA's target decision window from ten months to six, and the voucher can be redeemed for a different product than the one that earned it.

The price is the notable part. $205 million is more than double the roughly $100 million average at which vouchers changed hands for years before the market repriced through 2025.

What the voucher buys

Under the rare pediatric disease program, a sponsor that wins an approval for a rare pediatric disease drug can qualify for a voucher redeemable for priority review of a different product, and the sponsor may transfer or sell it. For a late-stage pipeline, that makes the voucher a scheduling instrument as much as a regulatory one: months carved out of the review calendar, attachable to whichever application the holder values most. Scholar Rock exercised that right within weeks of earning the asset; BioNTech is paying cash to acquire it.

Where it came from

The FDA approved ISEMBYLD (apitegromab-mstn) as the first therapy for spinal muscular atrophy that directly targets muscle loss, for adults and pediatric patients 2 years of age and older already receiving an SMN2-targeted treatment. The evidence base was a 52-week trial of 188 participants aged 2 to 21 who could not walk or move independently, with the primary analysis covering 156 patients aged 2 to 12. Treated patients in the 10 mg/kg arm were more than twice as likely as those on placebo to show a clinically meaningful improvement, 34.2 percent versus 13.5 percent, and the drug carries an increased risk of fractures, including serious fractures.

The voucher followed quickly. A notice published in the Federal Register on October 26 records that the FDA determined ISEMBYLD, approved September 11, 2026, meets the criteria for a priority review voucher under section 529 of the FD&C Act. Weeks after approval, Scholar Rock held a freshly minted, salable asset.

Why the price moved

Jazz Pharmaceuticals sold a priority review voucher for $200 million, a price disclosed at the JPMorgan Healthcare Conference in January 2026, and that figure now sits below the top of the market rather than at it. The record still belongs to 2015, when AbbVie paid $350 million for a voucher bought from United Therapeutics. Average deal value then settled around $100 million for years before the market began moving again through 2025: Zevra sold one for $150 million in February, Abeona at $155 million in May, and Bavarian Nordic netted $160 million in June.

Supply explains the bend. The rare pediatric disease voucher program sunsets after September 30, 2029 under the Consolidated Appropriations Act, 2026, enacted February 3, 2026, and the FDA may not award any vouchers under the program after that date. Existing vouchers become the only remaining supply, and buyers are repricing them accordingly.

Scholar Rock's side

Scholar Rock disclosed the terms in a filing on November 10: its subsidiary agreed to sell the rare pediatric disease voucher to BioNTech US Inc. for $205 million in cash upon closing, subject to expiration or termination of the HSR waiting period. The sale lands while the company's commercial engine is still warming up. Third-quarter US ISEMBYLD net product revenue was $570,000 against a net loss of $107.239 million, versus $102.220 million a year earlier, and the company held $413.599 million in cash, cash equivalents and marketable securities as of September 30. The US launch is underway, with initial patients infused in October; the European application was resubmitted and validated that month, with a CHMP opinion expected in the first half of 2027; Japan has accepted the application under priority review.

However the antitrust review goes, the transaction reads as a market trade rather than a discovery one. Vouchers have hardened into a tradeable asset class: issued by the regulator, earned through an approval, transferable at will, and now priced against a legislated cap on future issuance. BioNTech's $205 million tops the recent run of deals and bets that, for a late-stage oncology pipeline, months of review time are worth more than $205 million of cash.